Rationally Designed Ruthenium Complexes for Breast Cancer Therapy
Golara Golbaghi,Annie Castonguay +1 more
Reads0
Chats0
TLDR
An overview of the rationally designed ruthenium-based complexes that have been reported to date for which ligands were carefully selected for the treatment of hormone receptor positive breast cancers (estrogen receptor (ER+) or progesterone receptor (PR+)) is provided.Abstract:
Since the discovery of the anticancer potential of ruthenium-based complexes, several species were reported as promising candidates for the treatment of breast cancer, which accounts for the greatest number of new cases in women every year worldwide. Among these ruthenium complexes, species containing bioactive ligand(s) have attracted increasing attention due to their potential multitargeting properties, leading to anticancer drug candidates with a broader range of cellular targets/modes of action. This review of the literature aims at providing an overview of the rationally designed ruthenium-based complexes that have been reported to date for which ligands were carefully selected for the treatment of hormone receptor positive breast cancers (estrogen receptor (ER+) or progesterone receptor (PR+)). In addition, this brief survey highlights some of the most successful examples of ruthenium complexes reported for the treatment of triple negative breast cancer (TNBC), a highly aggressive type of cancer, regardless of if their ligands are known to have the ability to achieve a specific biological function.read more
Citations
More filters
Journal ArticleDOI
Exploring cellular uptake, accumulation and mechanism of action of a cationic Ru-based nanosystem in human preclinical models of breast cancer
Marialuisa Piccolo,Gabriella Misso,Maria Grazia Ferraro,Claudia Riccardi,Antonella Capuozzo,Mayra Rachele Zarone,Francesco Maione,Marco Trifuoggi,Paola Stiuso,Gerardino D'Errico,Gerardino D'Errico,Michele Caraglia,Luigi Paduano,Luigi Paduano,Daniela Montesarchio,Carlo Irace,Rita Santamaria +16 more
TL;DR: In vitro and in vivo preclinical investigations suggest that an original strategy based on suitable formulations of ruthenium(III)-complexes, inducing sustained cell death, could open new opportunities for breast cancer treatment, including the highly aggressive triple-negative subtype.
Journal ArticleDOI
New Organometallic Ruthenium(II) Compounds Synergistically Show Cytotoxic, Antimetastatic and Antiangiogenic Activities for the Treatment of Metastatic Cancer
Yuchen Wang,Jiahui Jin,Liwei Shu,Tongyu Li,Siming Lu,Mohamed Kasim Mohamed Subarkhan,Chao Chen,Hangxiang Wang +7 more
TL;DR: Data provided compelling evidence that the new cyclometalated ruthenium complex Ru 8 is an attractive agent because of synergistically suppressing bulky tumors and metastasized tumor nudes.
Journal ArticleDOI
Design concepts of half-sandwich organoruthenium anticancer agents based on bidentate bioactive ligands
William D.J. Tremlett,David M. Goodman,Tasha R. Steel,Saawan Kumar,Anna Wieczorek-Błauż,Fearghal P. Walsh,Matthew P. Sullivan,Muhammad Hanif,Christian G. Hartinger +8 more
TL;DR: Five design concepts are identified and explored and their application to half-sandwich organoruthenium anticancer compounds in which the bioactive ligand is coordinated to the Ru center through a bidentate chelating motif are explored.
Journal ArticleDOI
Combination of light and Ru(II) polypyridyl complexes: Recent advances in the development of new anticancer drugs
TL;DR: In this article , Ru(II) polypyridyl complexes (RPCs) have emerged as promising systems to be used in photodynamic therapy and, more recently, in photochemotherapy (PACT), taking advantage of the spatio-temporal control over the drug activation ensured by light.
References
More filters
Journal ArticleDOI
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray,Jacques Ferlay,Isabelle Soerjomataram,Rebecca L. Siegel,Lindsey A. Torre,Ahmedin Jemal +5 more
TL;DR: A status report on the global burden of cancer worldwide using the GLOBOCAN 2018 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer, with a focus on geographic variability across 20 world regions.
Journal ArticleDOI
Cancer statistics, 2019.
TL;DR: The overall cancer death rate dropped continuously from 1991 to 2016 by a total of 27%, translating into approximately 2,629,200 fewer cancer deaths than would have been expected if death rates had remained at their peak.
Journal ArticleDOI
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
O. Abe,R. Abe,K. Enomoto,K. Kikuchi,H. Koyama,H. Masuda,Y. Nomura,K. Sakai,K. Sugimachi,T. Tominaga,J. Uchino,M. Yoshida,J. L. Haybittle,C Davies,V. J. Harvey,T. M. Holdaway,R. G. Kay,B. H. Mason,John F. Forbes,Nicholas Wilcken,M. Gnant,Raimund Jakesz,M. Ploner,H. M. A. Yosef,C. Focan,J. P. Lobelle,U. Peek,G. D. Oates,Janet T. Powell,M. Durand,L. Mauriac,A. Di Leo,Stella Dolci,M.J. Piccart,M. B. Masood,D. Parker,J. J. Price,Pierre Hupperets,Sue Jackson,Joseph Ragaz,Donna L. Berry,Gloria Broadwater,C. Cirrincione,Hyman B. Muss,Larry Norton,Raymond B. Weiss,H. Abu-Zahra,S. M. Portnoj,Michael J. Baum,Jack Cuzick,Joan Houghton,David Riley,N. H. Gordon,H. L. Davis,A. Beatrice,J. Mihura,A. Naja,Y. Lehingue,P. Romestaing,J. B. Dubois,Thierry Delozier,J. Mace-Lesec'h,P. Rambert,O. Andrysek,J. Barkmanova,Julie Owen,P. Meier,A Howell,G. C. Ribeiro,R. Swindell,R Alison,J Boreham,Matthew Clarke,Rory Collins,Sarah C. Darby,P. Elphinstone,Vaughan Evans,Jon Godwin,Richard Gray,C. S. Harwood,C. Hicks,Spencer L. James,Elizabeth MacKinnon,Paul McGale,Theresa McHugh,Graham M. Mead,Richard Peto,Yisong Wang,J. Albano,C. F. de Oliveira,H. Gervasio,J. Gordilho,H Johansen,Henning T. Mouridsen,Rebecca Gelman,J.R. Harris,I. C. Henderson,Charles L. Shapiro,K. W. Andersen,C. K. Axelsson,M. Blichert-Toft,S. Moller,Jens Overgaard,Marie Overgaard,Carsten Rose,B. Cartensen,T. Palshof,H. J. Trampisch,Otilia Dalesio,E.G.E. de Vries,Sjoerd Rodenhuis,H. van Tinteren,R. L. Comis,Nancy E. Davidson,Nicholas J. Robert,George W. Sledge,Douglass C. Tormey,William C. Wood,David Cameron,Udi Chetty,P. Forrest,W. Jack,J. Rossbach,Jan G. M. Klijn,A. D. Treurniet-Donker,W. L. J. van Putten,Alberto Costa,Umberto Veronesi,H. Bartelink,L. Duchateau,C. Legrand,RJ Sylvester,J.A. van der Hage,C.J.H. van de Velde,M. P. Cunningham,R. Catalano,R. H. Creech,Jacques Bonneterre,P. Fargeot,Pierre Fumoleau,Pierre Kerbrat,Moïse Namer,Walter Jonat,Manfred Kaufmann,Martin Schumacher,G. von Minckwitz,G. Bastert,H. Rauschecker,R. Sauer,Willi Sauerbrei,A.J. Schauer,A. de Schryver,L. Vakaet,M. Belfiglio,A. Nicolucci,F. Pellegrini,M. Sacco,M. Valentini,C. S. McArdle,D. C. Smith,E. Galligioni,Francesco Boccardo,AU Rubagotti,D. M. Dent,C. A. Gudgeon,A. Hacking,A. Erazo,J. Y. Medina,M. Izuo,Y. Morishita,H. Takei,I.S. Fentiman,John L. Hayward,R D Rubens,D. Skilton,H. Graeff,Fritz Jänicke,C. Meisner,H. R. Scheurlen,D. von Fournier,Urania Dafni,G. Fountzilas,P. Klefstrom,Carl Blomqvist,T. Saarto,R. Margreiter,Bernard Asselain,R. J. Salmon,J. R. Vilcoq,Rodrigo Arriagada,Christopher Hill,A. Laplanche,M. G. Le,M. Spielmann,Paolo Bruzzi,E. Montanaro,R. Rosso,M. R. Sertoli,M. Venturini,Dino Amadori,J. Benraadt,M. Kooi,A. O. van de Velde,J. A. van Dongen,J. B. Vermorken,Monica Castiglione,F. Cavalli,A. S. Coates,J. Collins,JF Forbes,Richard D. Gelber,A. Goldhirsch,J. Lindtner,Karen N. Price,C. M. Rudenstam,H.-J. Senn,Judith M Bliss,Clair Chilvers,R. C. Coombes,Emma Hall,Michel Marty,R. V. Borovik,G. Brufman,H. Hayat,E. Robinson,N. Wigler,Gianni Bonadonna,T. Camerini,G. De Palo,M. Del Vecchio,F. Formelli,Pinuccia Valagussa,A Martoni,F. Pannuti,G. Cocconi,A. Colozza,R. Camisa,K. Aogi,S. Takashima,T. Ikeda,K. Inokuchi,K. Sawa,H. Sonoo,S. Korzeniowski,J. Skolyszewski,M. Ogawa,J. Yamashita,J. Bonte,R. Christiaens,Robert Paridaens,W. Van den Boegart,P. Martin,S. Romain,T. Hakes,Clifford A. Hudis,R. Wittes,G. Giokas,D. Kondylis,B. Lissaios,R. de la Huerta,M. G. Sainz,R. Altemus,K. Cowan,David N. Danforth,Allen S. Lichter,Marc E. Lippman,Joyce A. O'Shaughnessy,Lori J. Pierce,Seth M. Steinberg,D. Venzon,JoAnne Zujewski,A. Paradiso,M. De Lena,F. Schittulli,J. Myles,J. L. Pater,Kathleen I. Pritchard,Stewart J. Anderson,G. Bass,Anna Brown,John Bryant,J. Costantino,James J. Dignam,Bernard Fisher,C Redmond,Sam Wieand,Norman Wolmark,I. M. Jackson,Mike K. Palmer,JN Ingle,Vera J. Suman,Nils-Olof Bengtsson,H. Jonsson,Lars-Gunnar Larsson,J. P. Lythgoe,M. Kissin,Bjørn Erikstein,E Hannisdal,A. B. Jacobsen,J. E. Varhaug,S. Gundersen,Martin Hauer-Jensen,H. Host,R. Nissen-Meyer,Roger W. Blamey,A. Mitchell,Morgan Da,J.F.R. Robertson,M. Di Palma,G. Mathe,J. L. Misset,R. M. Clark,Mitch Levine,K Morimoto,Y. Takatsuka,E. Crossley,Al Harris,Denis Talbot,Mark Taylor,B. di Blasio,V. Ivanov,Vladimir Semiglazov,J. Brockschmidt,M. R. Cooper,H. Ueo,Carla I. Falkson,Roger A'Hern,Stanley W. Ashley,T. J. Powles,Ian E. Smith,John Yarnold,J.-C. Gazet,N. Cocoran,N. Deshpande,L. di Martino,P. Douglas,A. Lindtner,G Notter,A. J. S. Bryant,G. H. Ewing,L. A. Firth,J. L. Krushen-Kosloski,L. Foster,W.D. George,Helen J. Stewart,P. Stroner,Per-Uno Malmström,Torgil Möller,Stefan Rydén,Ingrid Tengrup,Lena Tennvall-Nittby,J. Carstenssen,M. Dufmats,Thomas Hatschek,Bo Nordenskjöld,Martin Söderberg,John T. Carpenter,KS Albain,J. Crowley,Stuart A. Green,Silvana Martino,CK Osborne,Peter M. Ravdin,U. Glas,Ulla Johansson,L E Rutqvist,T. Singnomklao,Arne Wallgren,Rudolf Maibach,Beat Thürlimann,Hermann Brenner,A. Hercbergs,M Yoshimoto,Gerrit DeBoer,Alexander H.G. Paterson,JW Meakin,T. Panzarella,Y. Shan,Y. F. Shao,X. Wang,D. B. Zhao,Z. M. Chen,H. C. Pan,J. Bahi,M. Reid,M. Spittle,G. P. Deutsch,F. Senanayake,D. L. W. Kwong,Angelo Raffaele Bianco,Chiara Carlomagno,M. De Laurentiis,S. De Placido,Aman U. Buzdar,Tae C Smith,Jonas Bergh,Lars Holmberg,Göran Liljegren,Jan Nilsson,M. Seifert,P. Sevelda,C. C. Zielinsky,R. B. Buchanan,M. Cross,G.T. Royle,Janet A. Dunn,Robert Kerrin Hills,Michael Lee,J. M. Morrison,D. Spooner,A. Litton,Rowan T. Chlebowski,H. Caffier +412 more
TL;DR: The 10-year and 15-year effects of various systemic adjuvant therapies on breast cancer recurrence and survival are reported and it is found that the cumulative reduction in mortality is more than twice as big at 15 years as at 5 years after diagnosis.
Journal ArticleDOI
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Hannah Farmer,Nuala McCabe,Christopher J. Lord,Andrew Tutt,Andrew Tutt,Damian A. Johnson,Tobias B. Richardson,Manuela Santarosa,Krystyna J. Dillon,Ian Hickson,Charlotte Knights,Niall M. B. Martin,Stephen P. Jackson,Graeme C. M. Smith,Alan Ashworth +14 more
TL;DR: BRCA1 or BRCA2 dysfunction unexpectedly and profoundly sensitizes cells to the inhibition of PARP enzymatic activity, resulting in chromosomal instability, cell cycle arrest and subsequent apoptosis, illustrating how different pathways cooperate to repair damage.
Journal ArticleDOI
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
Martine Piccart-Gebhart,Marion Procter,Brian Leyland-Jones,Aron Goldhirsch,Michael Untch,Ian E. Smith,Luca Gianni,José Baselga,Richard Bell,Christian Jackisch,David Cameron,Mitch Dowsett,Carlos H. Barrios,Günther G. Steger,Chiun-Shen Huang,Martin Andersson,Moshe Inbar,Mikhail Lichinitser,István Láng,U. Nitz,Hiroji Iwata,C Thomssen,Caroline Lohrisch,Thomas M. Suter,Josef Rüschoff,Tamás Süto ý,Victoria Greatorex,Carol Ward,Eleanor McFadden,M. Stella Dolci,Richard D. Gelber +30 more
TL;DR: One year of treatment with trastuzumab after adjuvant chemotherapy significantly improves disease-free survival among women with HER2-positive breast cancer.
Related Papers (5)
NAMI-A and KP1019/1339, Two Iconic Ruthenium Anticancer Drug Candidates Face-to-Face: A Case Story in Medicinal Inorganic Chemistry
Enzo Alessio,Luigi Messori +1 more